Therapeutic drug development is a long, expensive, and complex process that usually takes
12–15 years. In the early phases of drug discovery, in particular, there is a growing need for …

Covering: 1993 to 2021 (mainly 2017–2021) Alzheimer's and Parkinson's diseases are
neurodegenerative conditions affecting over 50 million people worldwide. Since these …

Disordered proteins are challenging therapeutic targets, and no drug is currently in clinical
use that modifies the properties of their monomeric states. Here, we identify a small …

Mitochondria are organelles with their own genomes, but they rely on the import of nuclear-
encoded proteins that are translated by cytosolic ribosomes. Therefore, it is important to …

The aggregation of α-synuclein, an intrinsically disordered protein that is highly abundant in
neurons, is closely associated with the onset and progression of Parkinson's disease. We …

To the Editor—Animal behavior is increasingly being recorded in systematic imaging studies
that generate large datasets. To maximize the usefulness of these data, there is a need for …

Alzheimer's disease (AD) is the most frequent cause of dementia. After decades of research,
we know the importance of the accumulation of protein aggregates such as β-amyloid …

The protein homeostasis (proteostasis) system encompasses the cellular processes that
regulate protein synthesis, folding, concentration, trafficking and degradation. In the case of …

Transient oligomeric species formed during the aggregation process of the 42-residue form
of the amyloid-β peptide (Aβ42) are key pathogenic agents in Alzheimer's disease (AD). To …

Behaviour is a sensitive and integrative readout of nervous system function and therefore an
attractive measure for assessing the effects of mutation or drug treatment on animals. Video …